Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease.

Humans Non-alcoholic Fatty Liver Disease / complications Fatty Liver, Alcoholic / complications Comorbidity Herpes Zoster / complications Age Factors Risk Factors
Alcoholic fatty liver disease Herpes zoster Non-alcoholic fatty liver disease

Journal

European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857

Informations de publication

Date de publication:
02 Dec 2023
Historique:
received: 20 04 2023
accepted: 11 11 2023
medline: 4 12 2023
pubmed: 3 12 2023
entrez: 2 12 2023
Statut: epublish

Résumé

Disease-related stress can trigger the occurrence of herpes zoster (HZ). Fatty liver disease (FLD) can have adverse effects on the human body and may induce stress in affected individuals. In this study, we investigated whether FLD is associated with an elevated risk of HZ. For this study, we utilized data from the National Health Insurance Research Database, patients with FLD from 2000 to 2017 were observed (follow-up until 2018). Patients were considered to have FLD if they had at least two outpatient visits or at least one admission record with a diagnostic code of FLD. Patients with FLD were matched 1:1 by age, sex, comorbidities, and index year with control patients. Additionally, the FLD was further categorized into non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) groups. Multivariable Cox proportional hazards model was used to calculate the incidence rate and adjusted hazard ratio (aHR) of HZ for FLD and AFLD and for various age groups, sex and comorbidities. Cumulative incidence curve for HZ was plotted through the Kaplan-Meier method, and p-value was calculated using the log-rank test. After 1:1 propensity-score matching, each cohort comprised 62,418 patients. The FLD cohort was further divided into NAFLD and AFLD groups, which respectively comprised 55,709 and 6709 patients. The FLD cohort had a risk of HZ significantly higher than that of the control cohort (aHR = 1.06; p < 0.001). Additionally, the NAFLD group exhibited a significantly higher risk of HZ than did the AFLD group (aHR = 1.22; p < 0.001). Among patients without any comorbidities, those with FLD had a higher risk of HZ than did those without FLD (aHR = 1.14; p < 0.001). Patients with FLD are at an increased risk of HZ development. Additionally, NAFLD is associated with a higher risk of HZ than AFLD. Therefore, patients with NAFLD should be informed of their increased risk of HZ.

Sections du résumé

BACKGROUND BACKGROUND
Disease-related stress can trigger the occurrence of herpes zoster (HZ). Fatty liver disease (FLD) can have adverse effects on the human body and may induce stress in affected individuals. In this study, we investigated whether FLD is associated with an elevated risk of HZ.
METHODS METHODS
For this study, we utilized data from the National Health Insurance Research Database, patients with FLD from 2000 to 2017 were observed (follow-up until 2018). Patients were considered to have FLD if they had at least two outpatient visits or at least one admission record with a diagnostic code of FLD. Patients with FLD were matched 1:1 by age, sex, comorbidities, and index year with control patients. Additionally, the FLD was further categorized into non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) groups. Multivariable Cox proportional hazards model was used to calculate the incidence rate and adjusted hazard ratio (aHR) of HZ for FLD and AFLD and for various age groups, sex and comorbidities. Cumulative incidence curve for HZ was plotted through the Kaplan-Meier method, and p-value was calculated using the log-rank test.
RESULTS RESULTS
After 1:1 propensity-score matching, each cohort comprised 62,418 patients. The FLD cohort was further divided into NAFLD and AFLD groups, which respectively comprised 55,709 and 6709 patients. The FLD cohort had a risk of HZ significantly higher than that of the control cohort (aHR = 1.06; p < 0.001). Additionally, the NAFLD group exhibited a significantly higher risk of HZ than did the AFLD group (aHR = 1.22; p < 0.001). Among patients without any comorbidities, those with FLD had a higher risk of HZ than did those without FLD (aHR = 1.14; p < 0.001).
CONCLUSION CONCLUSIONS
Patients with FLD are at an increased risk of HZ development. Additionally, NAFLD is associated with a higher risk of HZ than AFLD. Therefore, patients with NAFLD should be informed of their increased risk of HZ.

Identifiants

DOI: 10.1186/s40001-023-01524-6 PMID: 38042817 PMC: PMC10693036
pubmed: 38042817
doi: 10.1186/s40001-023-01524-6
pii: 10.1186/s40001-023-01524-6
pmc: PMC10693036
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

550

Informations de copyright

© 2023. The Author(s).

Références

J Diabetes Complications. 2022 May;36(5):108168
pubmed: 35370058
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:242-51
pubmed: 26375241
Front Med (Lausanne). 2022 Oct 06;9:985803
pubmed: 36275825
Int J Environ Res Public Health. 2023 Feb 01;20(3):
pubmed: 36768020
PLoS One. 2021 Nov 24;16(11):e0259942
pubmed: 34818359
Hepatol Commun. 2019 Jul 29;3(10):1334-1346
pubmed: 31592492
Clin Infect Dis. 2020 Oct 23;71(7):e125-e134
pubmed: 31677266
Adv Clin Exp Med. 2023 Apr;32(4):407-414
pubmed: 36413178
Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42
pubmed: 36517002
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752
pubmed: 32413340
Medicine (Baltimore). 2017 Sep;96(39):e8179
pubmed: 28953675
Handb Exp Pharmacol. 2018;248:347-367
pubmed: 29374837
J Affect Disord. 2022 Mar 15;301:8-13
pubmed: 34986375
BMJ Open. 2021 Dec 23;11(12):e046891
pubmed: 34949602
BMJ Open. 2014 Jun 10;4(6):e004833
pubmed: 24916088
Diabetes Metab J. 2017 Dec;41(6):430-437
pubmed: 29199410
J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2177-83
pubmed: 25917643
Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398
pubmed: 30902670
Postgrad Med. 2021 Aug;133(6):599-603
pubmed: 33605831
Vaccines (Basel). 2021 Aug 28;9(9):
pubmed: 34579200
Gut. 2021 May;70(5):962-969
pubmed: 32938692
Lancet Digit Health. 2023 Jan;5(1):e16-e27
pubmed: 36460578
Medicine (Baltimore). 2019 Oct;98(40):e17430
pubmed: 31577760
J Clin Psychiatry. 2015 Sep;76(9):e1099-104
pubmed: 26455673
Front Med (Lausanne). 2021 Sep 08;8:584322
pubmed: 34568351
Am J Epidemiol. 2021 Jun 1;190(6):1064-1074
pubmed: 33569573
Postgrad Med. 2021 Jan;133(1):96-101
pubmed: 32853042
Int J Clin Pract. 2020 Oct;74(10):e13566
pubmed: 32479686
Hum Vaccin Immunother. 2021 Jun 3;17(6):1714-1732
pubmed: 33651654
JAMA. 2019 May 7;321(17):1723-1725
pubmed: 31063562
Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296
pubmed: 35183303
J Clin Endocrinol Metab. 2022 Jan 18;107(2):586-597
pubmed: 34536279

Auteurs

Cheng-Wei Yu (CW)

Department of Nutrition, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chia-Yi City, 600, Taiwan.

Chia-Hung Chen (CH)

Department of Medical Education, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chia-Yi City, 600, Taiwan.
Department of Medical Imaging, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chia-Yi City, 600, Taiwan.

Yung-Chi Cheng (YC)

Department of Medical Education, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chia-Yi City, 600, Taiwan.
Department of Rehabilitation, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi City, 600, Taiwan.

Wen-Che Hsieh (WC)

Department of Chinese Medicine, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chia-Yi City, 600, Taiwan.

Tzu-Ju Hsu (TJ)

Management Office for Health Data, Clinical Trial Research Center, China Medical University Hospital, Taichung, 404, Taiwan.

Fuu-Jen Tsai (FJ)

School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, 404, Taiwan.
Department of Medical Research, China Medical University Hospital, Taichung, 404, Taiwan.
Division of Medical Genetics, China Medical University Children's Hospital, Taichung, 404, Taiwan.
Department of Biotechnology and Bioinformatics, Asia University, Taichung, 413, Taiwan.

Chao-Yu Hsu (CY)

Department of Medical Education, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chia-Yi City, 600, Taiwan. 07692@cych.org.tw.
Department of Artificial Intelligence and Healthcare Management, Central Taiwan University of Science and Technology 406, Taichung, Taiwan. 07692@cych.org.tw.
Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, 406, Taiwan. 07692@cych.org.tw.
Center for General Education, National Taichung University of Science and Technology, Taichung, 404, Taiwan. 07692@cych.org.tw.
Department of General Education, National Chin-Yi University of Technology, Taichung, 411, Taiwan. 07692@cych.org.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Non-alcoholic fatty liver disease associated...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Stéatose hépatique › Stéatose hépatique non alcoolique › Non-alcoholic fatty liver disease associated...
questionsmedicales.fr › Troubles dus à des produits chimiques › Troubles dus à l'abus d'alcool › Maladies alcooliques du foie › Stéatose hépatique alcoolique › Non-alcoholic fatty liver disease associated...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Comorbidité › Non-alcoholic fatty liver disease associated...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ADN › Infections à Herpesviridae › Infection à virus varicelle-zona › Zona › Non-alcoholic fatty liver disease associated...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Facteurs âges › Non-alcoholic fatty liver disease associated...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Non-alcoholic fatty liver disease associated...